Summary
Abbott Laboratories' third quarter 2010 report highlights significant strategic shifts, primarily driven by major acquisitions. The company saw a substantial increase in Net Sales, up 11.8% to $8.7 billion for the quarter and 14.7% to $25.2 billion for the nine months, largely fueled by the February acquisition of Solvay Pharmaceuticals and the September acquisition of Piramal Healthcare's Healthcare Solutions business. These acquisitions significantly expanded Abbott's global reach, particularly in emerging markets, and bolstered its pharmaceutical product portfolio. While revenue growth is robust, net earnings experienced a notable decline, down to $890.6 million in Q3 2010 from $1.5 billion in Q3 2009, and for the nine months, down to $3.2 billion from $4.2 billion. This decrease is attributed to significant acquisition-related expenses, integration costs, and a large restructuring charge related to the Solvay acquisition, totaling billions in goodwill and intangible assets. The company also faced ongoing challenges including generic competition for key drugs like Depakote and the voluntary recall of certain Similac infant formulas, which impacted nutritional product sales.
Financial Highlights
54 data points| Revenue | $8.67B |
| Cost of Revenue | $3.74B |
| Gross Profit | $4.93B |
| SG&A Expenses | $2.67B |
| Operating Expenses | $7.49B |
| Operating Income | $1.18B |
| Interest Expense | $149.10M |
| Net Income | $890.70M |
| EPS (Basic) | $0.58 |
| EPS (Diluted) | $0.57 |
| Shares Outstanding (Basic) | 1.55B |
| Shares Outstanding (Diluted) | 1.55B |
Key Highlights
- 1Net sales increased by 11.8% to $8.7 billion for the third quarter and 14.7% to $25.2 billion for the first nine months, driven by acquisitions and favorable exchange rates.
- 2Significant decrease in Net Earnings: Q3 net earnings were $890.6 million (down from $1.5 billion in Q3 2009), and nine-month net earnings were $3.2 billion (down from $4.2 billion in the prior year), primarily due to acquisition and restructuring costs.
- 3Major Acquisitions: Completed the acquisition of Solvay Pharmaceuticals for approximately $6.1 billion in February and Piramal Healthcare's Healthcare Solutions business for $2.2 billion plus contingent payments in September, significantly expanding global presence and product lines.
- 4Increased R&D Expenses: Research and development expenses rose significantly (59.7% in Q3, 33.6% for nine months) due to these acquisitions and continued pipeline investment.
- 5Restructuring Charges: A new restructuring plan related to the Solvay acquisition is expected to result in $810 million to $970 million in pretax charges over the next two years.
- 6Legal Proceedings: The company is involved in ongoing litigation, notably a patent dispute concerning Humira, where an adverse jury verdict was issued, though Abbott believes it will prevail on appeal. No reserves have been recorded for this case.
- 7Nutritional Product Recall: A voluntary recall of certain Similac-brand infant formulas in September impacted nutritional product sales.